Impact of disease-modifying drugs in patients with transthyretin amyloidosis after liver transplantation: a systematic review
Transplantation Reviews · 2025
DOI: 10.1016/j.trre.2025.100960 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Transplantation Reviews, 2025. Verfasst von Christiane Santo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Heart Institute of São Paulo, Incor, FMUSP, Brazil. Electronic address: espiritosantochristiane@gmail.com. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Liver Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Orthotopic liver transplant (OLT) was the first approved treatment for hereditary transthyretin amyloidosis (ATTRv). However, some patients continue to deteriorate due to ongoing wild-type TTR deposition and residual synthesis from extrahepatic sources. In recent years, disease-modifying therapies including TTR stabilizers (e.g., Tafamidis) and gene-silencing agents (e.g., Patisiran) have emerged, but their role in post-OLT patients remains unclear due to their exclusion from most clinical trials. METHODS: A systematic search was conducted in PubMed, Cochrane, and Embase (up to June 2025) using terms related to transthyretin amyloidosis, liver transplantation, and disease-modifying therapies. The objective was to evaluate clinical benefits and safety of these agents in symptomatic ATTRv patients after OLT. RESULTS: Disease-modifying therapies showed potential benefits in post-OLT ATTR patients. A total of 39 patients treated with tafamidis, inotersen, or patisiran were analyzed. Neurological improvements, including autonomic symptoms, NIS score, and quality of life, were based on 3 case reports and 32 patients from observational studies. Cardiovascular results were from 4 case reports, and biomarker findings from 3 case reports. CONCLUSIONS: Disease-modifying therapies may offer clinical benefits in post-OLT ATTRv patients. However, robust prospective studies and randomized trials are needed to confirm efficacy and ensure safety in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heart Institute of São Paulo, Incor, FMUSP, Brazil. Electronic address: espiritosantochristiane@gmail.com.
- Heart Institute of São Paulo, Incor, FMUSP, Brazil.
Zitieren
APA
Santo, C., Romero, C., Vaz Kerges Bueno, B., Dabarian, A., & Fernandes, F. (2025). Impact of disease-modifying drugs in patients with transthyretin amyloidosis after liver transplantation: a systematic review. Transplantation Reviews. https://doi.org/10.1016/j.trre.2025.100960
Vancouver
Santo C, Romero C, Vaz Kerges Bueno B, Dabarian A, Fernandes F. Impact of disease-modifying drugs in patients with transthyretin amyloidosis after liver transplantation: a systematic review. Transplantation Reviews. 2025. doi:10.1016/j.trre.2025.100960
BibTeX
@article{Santo2025,
author = {Santo, Christiane and Romero, Cristhian and Vaz Kerges Bueno, Bruno and Dabarian, Andre and Fernandes, Fabio},
title = {Impact of disease-modifying drugs in patients with transthyretin amyloidosis after liver transplantation: a systematic review},
journal = {Transplantation Reviews},
year = {2025},
doi = {10.1016/j.trre.2025.100960}
}
EUVIMED